Atlas Trials

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Clinical trial NCT04477850 · COMPLETED

Trial details

NCT number
NCT04477850
Sponsor
Celgene
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Myelodysplastic Syndromes
Start date
2020-11-30
Primary completion
2023-09-29
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.